NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD

NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Preparing for NDA Submission for Leading Drug Candidate

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the process of preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”). The NDA is for PAX-101, an intravenous formulation of suramin that could potentially treat conditions such as Human African Trypanosomiasis and autism spectrum disorder (“ASD”). The process includes having a Type C meeting with the FDA, and then incorporating the outcomes of that meeting, which is a key opportunity for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101.

“PaxMedica’s primary mission is to address the unmet medical needs in ASD,” the article states. “The company is developing PAX-101 for ASD, with a completed phase 2B study showing promising results. Additionally, PAX-102, an intranasal formulation of suramin, is under evaluation for ASD and other neurodevelopmental conditions. The company’s commitment extends to exploring selective APTs that target specific purinergic receptors, potentially offering enhanced therapeutic benefits.”

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer